New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 4, 2014
Oracle HCM World is being held in Las Vegas on February 4-6.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 >>
September 23, 2015
17:37 EDTVZSynchronoss confirms multi-year contract with Verizon
Subscribe for More Information
16:34 EDTVZOn The Fly: Top stock stories for Wednesday
Stocks began the day in quiet fashion and remained that way during the first hour of trading. Following the release of the weekly energy inventory report, the averages moved lower and looked to be possibly setting up for another selloff. Positive comments on China's economy by its President, who is visiting the U.S., brought out buyers, who pared the market's losses. The averages finished slightly in the red in a day marked by low volume as a number of market participants may have been absent in observance of the Jewish holiday of Yom Kippur. ECONOMIC EVENTS: In the U.S., Markit's flash manufacturing purchasing manager's index was flat at 53.0 in September, which was slightly better than the expectation for it to dip to 52.8. EIA inventory data showed a 1.93M barrel fall in crude oil inventories, versus expectations for a weekly drawdown of 1.25M barrels. In China, Markit's flash manufacturing PMI fell to 47.0 in September from 47.3 last month. In Europe, Markit's composite PMI for the eurozone came in at 53.9 in the first look for September, down from 54.3 in August and below expectations for a reading of 54.1. COMPANY NEWS: Shares of Volkswagen (VLKAY) trading in New York rebounded 6.5% to $27.10 following the resignation of Chief Executive Officer Martin Winterkorn, with the company's supervisory board subsequently praising the decision and saying it will consider his replacement at a meeting Friday. Prior to the CEO change news, the stock was downgraded at research firms JPMorgan, Deutsche Bank and Natixis to hold or equivalent ratings this morning. Accounting for today's advance, U.S.-listed shares of Volkwagen are still down nearly 29% since last Friday, when the EPA publicly accused the automaker of equipping certain diesel cars sold in the U.S. with software that circumvented emissions standards... Against the backdrop of China's President Xi Jinping visiting the U.S., Boeing (BA) announced deals to sell 300 planes to three Chinese companies and set up an aircraft factory in China. The deals are possibly worth tens of billions of dollars in total and represent the largest total order the planemaker has received from Chinese companies, according to Reuters. The Wall Street Journal reported, citing people familiar with the matter, that Cisco (CSCO) plans to announce a partnership with Chinese server maker Inspur Group during President Xi Jinping's visit. MAJOR MOVERS: Among the notable gainers was First Niagara (FNFG), which advanced $1.30, or 14.5%, to $10.26 following a Bloomberg report that the company is exploring a sale. DealReporter noted that potential suitors include Toronto-Dominion Bank (TD), Huntington Bancshares (HBAN) and New York Community Bancorp (NYCB). BioMed Realty (BMR) gained $2.36, or 12.3%, to $21.54 after Bloomberg reported that the company is in talks to sell itself and has attracted attention from firms including Blackstone (BX). Heron Therapeutics (HRTX) rose $7.25, or 21.6%, to $40.81 after announcing that its Phase 2 study of HTX-011 for post-operative pain met its primary endpoint. Shares of a competitor Pacira (PCRX) declined 7.65% after the news, with several analysts remarking that Heron's data compares favorably versus Pacira's Exparel drug. Summit Midstream Partners (SMLP) declined $3.90, or 18.2%, to $17.52 following a Bloomberg report that Energy Capital Partners is seeking to sell its stake in the company. Synchronoss (SNCR) fell 10.75% to $33.37 after research firm Baird said it has become "increasingly concerned" that Verizon (VZ) is "no longer fully committed" to the white-label cloud product it offers in conjunction with the cloud services provider. INDEXES: The Dow fell 50.58, or 0.31%, to 16,279.89, the Nasdaq lost 3.98, or 0.08%, to 4,752.74, and the S&P 500 declined 3.98, or 0.2%, to 1,938.76.
12:27 EDTVZOn The Fly: Top stock stories at midday
Subscribe for More Information
12:02 EDTVZIntel joins Verizon 5G Technology Forum
Subscribe for More Information
11:48 EDTVZSynchronoss drops after concerns raised about Verizon cloud business
After Verizon (VZ) recently reduced the amount of free cloud storage it provides to customers as part of its cost cutting efforts, analysts at Baird told investors they were "increasingly concerned" that the telecom giant is "no longer fully committed" to the white-label cloud product it offers via its agreement with cloud services provider Synchronoss Technologies (SNCR). Analysts at two other firms have issued defenses of Synchronoss in the wake of its sharp decline today. BEARISH VIEW: After Version cut its free cloud storage to 5GB from 25GB, Baird said it believed the Telco is less committed to Synchronoss' cloud offering, which the firm contended will "likely have revenue implications for 2016." The firm, which said it has had a negative bias on Synchronoss due to long-term cloud competitive concerns and the lack of growth outside of AT&T (T) and Verizon, has a Neutral rating on the cloud services provider's shares. DEFENSES: JPMorgan analyst Sterling Auty attributes today's pullback in shares of Synchronoss to the concerns raised about the potential loss of Verizon as a cloud customer. Auty, however, sees "no chance" of Synchronoss losing Verizon as a customer in the near-term since the wireless carrier recently renewed its contract with the company for multiple years. He views today's selloff as a "significant overreaction" and recommends buying Synchronoss at current levels. Also noting concerns raised about Synchronoss' potential loss of some cloud business, Wells Fargo said even if Synchronoss' cloud business exhibited zero growth in 2016 from 2015, shares would be compelling at current levels. The firm views the selloff as overdone and reiterates its Overweight rating on Synchronoss shares. PRICE ACTION: Synchronoss shares, which dipped as low as $27.86 this morning, are off their worst levels but remain down $4.65 to $32.74 in late morning trading.
10:52 EDTVZSynchronoss Technologies volatility spikes on sharp pull back
Subscribe for More Information
10:51 EDTVZJPMorgan says 'no chance' Synchronoss loses Verizon in near-term
JPMorgan analyst Sterling Auty attributes today's pullback in shares of Synchronoss Technologies (SNCR) to a research note from Baird talking about the potential loss of Verizon (VZ) as a cloud customer. The comments come after the wireless carrier changed the pricing in the Verizon cloud offering. Auty sees "no chance" of Synchronoss losing Verizon as a customer in the near-term since the wireless carrier recently renewed its contract with the company for multiple years. He views today's selloff as a "significant overreaction" and recommends buying Synchronoss at current levels. Shares are off their lows but remain down $5.91 to $31.48 in morning trading.
10:20 EDTORCLOptions with decreasing implied volatility
Options with decreasing implied volatility: CVC HRTX NWBO ATML RHT KMX OVTI ADBE ORCL DRI
09:18 EDTGMPaulson Institute and CCPIT to co-host U.S.-China Business Roundtable
The Paulson Institute and the China Council for the Promotion of International Trade (CCPIT) provide an opportunity for U.S. and Chinese business leaders to discuss issues facing the two countries in a roundtable being held in Seattle, Washington on September 23.
September 22, 2015
20:02 EDTUNHClinton vows $250 cap on monthly drug costs in blast against biotechs, insurers
Democratic presidential candidate Hillary Clinton railed against biotech companies as well as health insurers at a community health care forum in Iowa on Tuesday. Clinton began her speech by praising the Affordable Care Act, but quickly noted that she wants to strengthen it due to what she called the rising cost of prescription drugs. She explained, "Our pharmaceutical and biotechnology industries deserve credit... [But] too often, these drugs cost a fortune. Now, sometimes there is a good reason for that. Scientific breakthroughs are often the result of major investment... so it may makes sense, for a short period of time, to have to charge a lot of money for a drug. But when a drug has no competition, when there aren't any other treatments that can do what it does, pharmaceutical companies can charge astronomical fees far beyond anything that it would take to recoup their investment, and far beyond what they charge consumers anywhere else in the world outside of America." Referencing the recent criticism against Turing Pharmaceuticals, Clinton went on to say that "pharmaceutical companies that acquire an existing affordable drug that people rely on, and then turn around and charge a fortune for it, [are just betting] on the fact that desperate people will find some way to pay for it." Preemptively responding to questions of whether greater regulation will dampen investment, Clinton commented that "some people worry that my proposals will threaten innovation, but I have designed a plan that will do exactly the opposite... Under my plan, drug companies that want to keep getting federal support will have to redirect more of their profits into meaningful investments in research and development." Clinton also criticized incremental drug improvements, saying that "too often, so-called new drugs are really old drugs that have just been tweaked a little bit, but then they're marketed as breakthrough drugs and they're sold for high prices." The Democratic candidate went on to condemn advertising in the drug industry, remarking that "I also want to tackle direct to consumer advertising... Other countries ban these ads because they are so often misleading. But at the very least, we shouldn't be encouraging them with corporate write-offs... Under my plan, we will instead use that taxpayer money to fund innovation... I would also like to make sure any ads the drug industry does run are approved by the FDA." Moving more broadly onto Medicaid and health insurers, Clinton stated, "I believe Medicare should be able to negotiate for lower prices for its members... I will require drug companies to provide higher rebates for prescription drugs to low income Medicare patients, just like they have to do for Medicaid patients... I think the insurance companies need to be put on notice." Providing more concrete details of her plan, Clinton concluded, "I will cap out of pocket drug costs for working families. You won't have to pay more than $250 a month for covered medications... Particularly for people who have a chronic illness. Also under my plan, you will be able to import cheaper drugs from other countries legally. If the medicine you need costs less in Canada, you should be able to buy it from Canada or any other country that meets our safety standards... I will also make sure we have more generics on the market [by boosting funding for] the FDA's office of generic drugs."
14:34 EDTVZVerizon spins out CrunchBase, says AOL to retain significant ownership interest
Subscribe for More Information
09:52 EDTVZCNBC's Faber dampens DISH takeover speculation
Potential deal talks between DISH (DISH) and T-Mobile (TMUS) were going nowhere in the past and are still not going anywhere, CNBC's David Faber reports. Speculation continues to surround DISH after it asked the FCC for more time to pay for its newly purchased spectrum, citing "new and complex business issues," Faber added. Verizon (VZ) CEO Lowell McAdam told the reporter last week in an interview that his company has no plans to buy a satellite company and is not in talks with DISH. Shares of DISH are down 57c to $61.85 in early trading.
08:37 EDTUNHAetna, Anthem CEOs set to testify to Senate committee, WSJ reports
Subscribe for More Information
07:52 EDTATVIActivision Blizzard price target raised to $36 from $30 at Baird
Subscribe for More Information
07:46 EDTGMFormer GM exec: Apple will lose money in car business, CNBC says
Apple (AAPL) could lose big money if it enters the electric car business, CNBC reports, citing comments from former General Motors (GM) vice chairman Bob Lutz. "There is absolutely no reason to assume that Apple is going to be financially successful in the electric car business," Lutz told CNBC. Reference Link
07:34 EDTCSDenver Gold Group to hold a forum
Subscribe for More Information
07:27 EDTVZVerizon valuation 'still compelling,' says Wells Fargo
Subscribe for More Information
September 21, 2015
12:08 EDTTGTTarget to test robot workers at concept store, Fortune reports
Subscribe for More Information
09:01 EDTMMacy's to hire 85,000 seasonal associates in 2015
Macy's said it plans to hire seasonal associates for approximately 85,000 positions at its Macy's and Bloomingdale's stores, call centers, distribution centers and online fulfillment centers nationwide for the 2015 Christmas and holiday season. The company's 2015 seasonal hiring plan is essentially flat to last year.
06:34 EDTVZSamsung may be planning leasing program for Galaxy phones, Forbes reports
Samsung (SSNLF) is rumored to be planning to launch a leasing program for its Galaxy phones in the U.S., similar to the program Apple (AAPL) recently announced, Forbes reports, citing an industry executive with knowledge of Samsung's plans. According to the source, Samsung could launch the leasing program in the next few months. Apple's iPhone Upgrade Program encourages consumers to buy iPhones directly from the Apple Store instead of going through carriers, the publication notes. Publicly traded wireless carriers include AT&T (T), Verizon (VZ), Sprint (S) and T-Mobile US (TMUS). Reference Link
1 | 2 | 3 | 4 | 5 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use